title: [Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI].
abstract: A phase II study of a new anthracycline anti-cancer antibiotics, epirubicin (EPI), was undertaken in 71 patients with urothelial malignancies; 40 with advanced urothelial malignancies and 31 with superficial bladder cancer. Out of them 32 patients with advanced stage of urothelial cancer were evaluated for the systemic use of EPI, while 30 patients with superficial bladder cancer for intravesical use. Intravenous administration of this new anticancer antibiotic, at a dosage of 60 mg/m2 every three weeks, showed the response rate of 20.0% for advanced bladder cancer and 14.3% for renal pelvic and ureteral tumors. In cases of superficial bladder cancer, at a dosage of 60 mg/30 ml X 3 day every week in principal, the response rate was 66.7%. Eight out of 30 patients showed complete disappearance of the tumor. Twelve patients also showed more than 50% tumor regression. As for adverse effects no serious cardiotoxicity was demonstrated. Anorexia and other gastrointestinal side effects, such as nausea and vomiting, were also seen. Alopecia and myelosuppression were the major adverse effects among patients with systemic EPI administration. With intravesical use of EPI, cystitis syndrome was the major toxicity. However, no systemic side effects were noted in these cases. In conclusion, EPI was assumed to be effective for the treatment of advanced urothelial tumors and superficial bladder cancer.
authors.affiliation: Department of Urology, Faculty of Medicine, the University of Tokyo
authors.forename: T
authors.initials: T
authors.lastname: Niijima
authors.affiliation: Department of Urology, Hokkaido University School of Medicine
authors.forename: T
authors.initials: T
authors.lastname: Koyanagi
authors.affiliation: Department of Urology, Hokkaido University School of Medicine
authors.forename: A
authors.initials: A
authors.lastname: Maru
authors.affiliation: Department of Urology, Hokkaido University School of Medicine
authors.forename: S
authors.initials: S
authors.lastname: Sakashita
authors.affiliation: Department of Urology, Institute of Clinical Medicine, University of Tsukuba
authors.forename: K
authors.initials: K
authors.lastname: Koiso
authors.affiliation: Department of Urology, Institute of Clinical Medicine, University of Tsukuba
authors.forename: H
authors.initials: H
authors.lastname: Ishikawa
authors.affiliation: Department of Urology, Institute of Clinical Medicine, University of Tsukuba
authors.forename: K
authors.initials: K
authors.lastname: Uchida
authors.affiliation: Department of Urology, School of Medicine, Chiba University
authors.forename: J
authors.initials: J
authors.lastname: Shimazaki
authors.affiliation: Department of Urology, School of Medicine, Chiba University
authors.forename: S
authors.initials: S
authors.lastname: Isaka
authors.affiliation: Department of Urology, Faculty of Medicine, the University of Tokyo
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.affiliation: Department of Urology, The Jikei University School of Medicine
authors.forename: T
authors.initials: T
authors.lastname: Machida
authors.affiliation: Department of Urology, The Jikei University School of Medicine
authors.forename: K
authors.initials: K
authors.lastname: Tashiro
authors.affiliation: Department of Urology, First Hospital of Nippon Medical School
authors.forename: Y
authors.initials: Y
authors.lastname: Nakagami
authors.affiliation: Department of Urology, First Hospital of Nippon Medical School
authors.forename: T
authors.initials: T
authors.lastname: Lin
authors.affiliation: Department of Urology. Yokohama City University School of Medicine
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
authors.affiliation: Department of Urology. Yokohama City University School of Medicine
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.affiliation: Department of Urology, Nagoya Second Red Cross Hospital
authors.forename: K
authors.initials: K
authors.lastname: Obata
authors.affiliation: Department of Urology, Nagoya Second Red Cross Hospital
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.affiliation: Department of Urology, Osaka University School of Medicine
authors.forename: T
authors.initials: T
authors.lastname: Sonoda
authors.affiliation: Department of Urology, Osaka University School of Medicine
authors.forename: M
authors.initials: M
authors.lastname: Matsuda
authors.affiliation: Department of Urology, Osaka University School of Medicine
authors.forename: H
authors.initials: H
authors.lastname: Fujioka
authors.affiliation: Department of Urology, The Center for Adult Diseases, Osaka
authors.forename: T
authors.initials: T
authors.lastname: Kotake
authors.affiliation: Department of Urology, The Center for Adult Diseases, Osaka
authors.forename: M
authors.initials: M
authors.lastname: Kuroda
authors.affiliation: Department of Urology, Okayama University Medical School
authors.forename: H
authors.initials: H
authors.lastname: Ohmori
authors.affiliation: Department of Urology, Okayama University Medical School
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumura
authors.affiliation: Department of Urology, Okayama University Medical School
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
authors.affiliation: Department of Urology, National Hospital Shikoku Cancer Center
authors.forename: T
authors.initials: T
authors.lastname: Uyama
authors.affiliation: Department of Urology, Faculty of Medicine, Kyushu University
authors.forename: J
authors.initials: J
authors.lastname: Kumazawa
authors.affiliation: Department of Urology, Faculty of Medicine, Kyushu University
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.affiliation: Department of Urology, Faculty of Medicine. Kagoshima University
authors.forename: Y
authors.initials: Y
authors.lastname: Ohi
authors.affiliation: Department of Urology, Faculty of Medicine. Kagoshima University
authors.forename: T
authors.initials: T
authors.lastname: Shimoinaba
mesh_terms: D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007682:Kidney Pelvis; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D014516:Ureteral Neoplasms / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D006454:Hemoglobins; D015251:Epirubicin; D004317:Doxorubicin